Back to top
more

Amicus Therapeutics (FOLD)

(Real Time Quote from BATS)

$9.58 USD

9.58
1,131,971

+0.25 (2.68%)

Updated May 15, 2024 02:03 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Horizon's (HZNP) Q3 Earnings Beat Estimates, 2021 Guidance Up

by Zacks Equity Research

Horizon's (HZNP) earnings and revenues beat estimates in the third quarter of 2021. The company lifts net sales guidance for 2021.

Sarepta (SRPT) Q3 Earnings Beat, 2021 Sales View Raised

by Zacks Equity Research

Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in the third quarter. The company also raises revenues guidance for the year. Stock up in after-market trading.

Ultragenyx's (RARE) Q3 Earnings & Revenues Beat Estimates

by Zacks Equity Research

Ultragenyx (RARE) reports narrower-than-expected loss in the third quarter of 2021 while revenues surpass estimates.

Bausch's (BHC) Q3 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Bausch (BHC) beats on earnings but misses on sales in the third quarter. The company reiterates annual revenue guidance.

Dr. Reddy's (RDY) Q2 Earnings, Sales Increase Year Over Year

by Zacks Equity Research

Dr. Reddy's (RDY) earnings and revenues increase year over year in second-quarter fiscal 2022.

Will Amicus Therapeutics (FOLD) Report Negative Q3 Earnings? What You Should Know

by Zacks Equity Research

Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin (BMRN) Beats on Q3 Earnings, Ups 2021 Guidance

by Zacks Equity Research

BioMarin's (BMRN) earnings beat estimates in the third quarter of 2021 while revenues miss the same. The company raises total revenue guidance and increases adjusted earnings guidance for 2021.

Can Amicus Therapeutics (FOLD) Climb 77% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 77.1% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Galera (GRTX) Tanks As Oral Mucositis Study Fails to Meet Goal

by Zacks Equity Research

Galera's (GRTX) phase III ROMAN study on avasopasem for treating radiotherapy-induced severe oral mucositis in patients with head and neck cancer fails to meet its primary endpoint. Shares fall.

    Radius' (RDUS) Study on Tymlos for Osteoporosis in Men Meets Goal

    by Zacks Equity Research

    Radius (RDUS) reports positive top-line results from the ATOM study evaluating Tymlos (abaloparatide) subcutaneous injection for use in men with osteoporosis. The study met the primary endpoint.

    Oyster Point's (OYST) Tyrvaya Gets FDA Nod for Dry Eye Disease

    by Zacks Equity Research

    The FDA approves Oyster Point's (OYST) Tyrvaya nasal spray for the treatment of the signs and symptoms of dry eye disease.

      Bristol Myers (BMY) Gets Positive CHMP Opinion for Zeposia in UC

      by Zacks Equity Research

      The CHMP gives a positive opinion on, and recommends granting approval to Bristol Myers' (BMY) Zeposia for the treatment of adults with moderately to severely active ulcerative colitis.

        Wall Street Analysts Predict a 59% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know

        by Zacks Equity Research

        The average of price targets set by Wall Street analysts indicates a potential upside of 59.3% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

        Amcius (FOLD) to Spin-Off Gene Therapy Arm, Form New Firm With ARYA

        by Zacks Equity Research

        Amicus (FOLD) plans to separate its gene therapy business into a new company formed in alliance with ARYA Sciences Acquisition Corp.

        Sanofi (SNY) Pompe Disease Drug Receives FDA's Approval

        by Zacks Equity Research

        The FDA gives approval to Sanofi's (SNY) Nexviazyme (avalglucosidase alfa) for treating late-onset Pompe disease.

        Amicus (FOLD) Q2 Earnings & Revenues Top Estimates, Stock Up

        by Zacks Equity Research

        Amicus (FOLD) reports narrower-than-expected Q2 loss. The sales figure also beat estimates. Following encouraging results and positive progress with pipeline candidates, the stock rises.

        Amicus Therapeutics (FOLD) Reports Q2 Loss, Tops Revenue Estimates

        by Zacks Equity Research

        Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of 9.52% and 8.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

        Analysts Estimate Amicus Therapeutics (FOLD) to Report a Decline in Earnings: What to Look Out for

        by Zacks Equity Research

        Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

        Why Is Amicus Therapeutics (FOLD) Up 8.1% Since Last Earnings Report?

        by Zacks Equity Research

        Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

        Amicus' (FOLD) Q1 Loss Wider Than Expected, Sales Up Y/Y

        by Zacks Equity Research

        Amicus (FOLD) reports a wider Q1 loss and sales miss estimates.

        Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates

        by Zacks Equity Research

        Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -8.70% and -7.47%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

        Amicus Therapeutics (FOLD) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

        by Zacks Equity Research

        Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

        Amicus' (FOLD) Q4 Earnings Miss Estimates, Sales Beat on Galafold

        by Zacks Equity Research

        Amicus (FOLD) reports a wider-than-expected Q4 loss but sales beat estimates.

        Amicus Therapeutics (FOLD) Reports Q4 Loss, Tops Revenue Estimates

        by Zacks Equity Research

        Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -12.50% and 0.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

        Will Amicus Therapeutics (FOLD) Report Negative Earnings Next Week? What You Should Know

        by Zacks Equity Research

        Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.